Abstract
Isoniazid is one of the most effective antituberculosis drugs, yet its precise mechanism of action is still controversial. Using specialized linkage transduction, a single point mutation allele (S94A) within the putative target gene inhA was transferred in Mycobacterium tuberculosis. The inhA(S94A) allele was sufficient to confer clinically relevant levels of resistance to isoniazid killing and inhibition of mycolic acid biosynthesis. This resistance correlated with the decreased binding of the INH-NAD inhibitor to InhA, as shown by enzymatic and X-ray crystallographic analyses, and establishes InhA as the primary target of isoniazid action in M. tuberculosis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bernstein, J.W., Lott, A., Steinberg, B.A. & Yale, H.L. Am. Rev. Tuberc. 65, 357–374 (1952).
Takayama, K., Wang, L. & David, H.L. Antimicrob. Agents Chemother. 2, 29–35 (1972).
Takayama, K., Schnoes, H.K., Armstrong, E.L. & Boyle, R.W. J. Lipid Res. 16, 308–317 (1975).
Banerjee, A. et al. Science 263, 227–230 (1994).
Cole, S.T. et al. Nature 393, 537–544 (1998).
Mdluli, K. et al. Science 280, 1607–1610 (1998).
Argyrou, A., Vetting, M.W., Aladegbami, B. & Blanchard, J.S. Nat. Struct. Mol. Biol. 13, 408–413 (2006).
Ramaswamy, S.V. et al. Antimicrob. Agents Chemother. 47, 1241–1250 (2003).
Bardarov, S. et al. Microbiology 148, 3007–3017 (2002).
Larsen, M.H. et al. Mol. Microbiol. 46, 453–466 (2002).
Wilming, M. & Johnsson, K. Angew. Chem. Int. Edn Engl. 38, 2588–2590 (1999).
Rozwarski, D.A., Grant, G.A., Barton, D.H., Jacobs, W.R., Jr . & Sacchettini, J.C. Science 279, 98–102 (1998).
Zhang, Y., Heym, B., Allen, B., Young, D. & Cole, S. Nature 358, 591–593 (1992).
Vilcheze, C. et al. J. Bacteriol. 182, 4059–4067 (2000).
Vilcheze, C. et al. Antimicrob. Agents Chemother. 49, 708–720 (2005).
Acknowledgements
We gratefully acknowledge G. Morlock for sending us the DNA from the INH-resistant clinical isolate carrying the inhA(S94A) mutation. L. Kremer is supported by a grant from the Centre National de la Recherche Scientifique (ATIP “Microbiologie Fondamentale”). J.C.S. acknowledges the Robert A. Welch Foundation grant A-0015. We also acknowledge support for this work from US National Institutes of Health grants AI43268 and AI46669, and from the Structural Genomics Project grant 1P50GM6241. We also thank G. Hatfull for careful reading of this manuscript.
Author information
Authors and Affiliations
Contributions
C.V. performed specialized transductions of inhA in M. tuberculosis and BCG and analyzed the transductants for their inserts, INH and ETH resistance and biochemical resistance to INH, and wrote most of the manuscript with W.R.J. F.W. prepared the INH-NAD adduct, performed the InhA enzymological analyses and X-ray crystallography. M.A. constructed the phages for transduction and performed and analyzed the kasA allelic exchanges in M. tuberculosis and M. bovis BCG. T.R.W. sequenced the transductants. M.H.H. and R.C. conducted the hairpin-shaped primer assays and mRNA experiments. L.K. provided the pMV261::kasA constructs and did the western blot analysis. D.A., J.C.S. and W.R.J. contributed to the design of the study, data analysis and data interpretation.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Fig. 1
Drug susceptibility of M. bovis BCG inhA(S94A). (PDF 1773 kb)
Supplementary Table 1
Strains depictions and respective minimum inhibitory concentrations (MICs) for INH and ETH. (PDF 62 kb)
Rights and permissions
About this article
Cite this article
Vilchèze, C., Wang, F., Arai, M. et al. Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid. Nat Med 12, 1027–1029 (2006). https://doi.org/10.1038/nm1466
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm1466
This article is cited by
-
Structure-based drug design and characterization of novel pyrazine hydrazinylidene derivatives with a benzenesulfonate scaffold as noncovalent inhibitors of DprE1 tor tuberculosis treatment
Molecular Diversity (2024)
-
Insights into the Inhibition of Mycolic Acid Synthesis by Cytosporone E Derivatives for Tuberculosis Treatment Via an In Silico Multi-target Approach
Chemistry Africa (2023)
-
Discovery of novel and potent InhA direct inhibitors by ensemble docking-based virtual screening and biological assays
Journal of Computer-Aided Molecular Design (2023)
-
The pathogenic mechanism of Mycobacterium tuberculosis: implication for new drug development
Molecular Biomedicine (2022)
-
In-silico and in-vitro analysis of novel substituted benzimidazolyl derivatives for antimycobacterial potentials targeting enoyl acyl carrier protein reductase (InhA)
Future Journal of Pharmaceutical Sciences (2022)